Dechra Veterinary Products has launched Mirataz, the first and only licensed transdermal mirtazapine
ointment for cats in Europe and can induce significant weight gain in as little
as 14 days (Poole et al., 2019)
Mirataz ointment is
licensed treatment for managed body weight gain in cats suffering from poor
appetite and weight loss as a result of chronic medical conditions.
The ointment, which allows
for a swift response to the initial symptoms of weight loss and lack of
appetite, can improve the condition and wellbeing of the patient before a definitive
diagnosis has been made.
Dechra
Brand Manager Claire Morgan said: “Unintended feline weight loss may be
associated with serious consequences including reduced survival time.
Identifying and treating weight loss early, as well as precise weight
management in the longer term, can help improve feline patient’s overall health
and comfort. With unintended weight loss, you can’t afford to delay treatment.”
Mirataz enters the market as the
only veterinary licensed weight gain product in Europe, with alternatives originating
in the made to order veterinary specials and human medication markets.
Mirataz is available in a 5g tube and comes in child resistant packaging. It is available
now in wholesalers and more information can be found online.
